Stacytine 200 CAP

Stacytine 200 CAP contains acetylcysteine which reduces the viscosity of pulmonary secretions and facilitates their removal. Acetylcysteine may protect the liver in case of overdose of paracetamol by maintaining or restoring glutathione levels or by acting as an alternate substrate for conjugation with the toxic intermediate metabolite.

Pack size Box of 100 capsules (10 blisters x 10 caps. Bottle of 100 caps)
Shelf-life 24 months
Composition Acetylcysteine
Dosage forms and strengths Hard-gelatin capsule: 200 mg
Product code :



Acetylcysteine is used as a mucolytic agent in the adjunctive treatment of patients with inspissated mucous secretions in such conditions as acute and chronic bronchopulmonary disorders.

Acetylcysteine is used as an antidote for the treatment of paracetamol overdosage.


Mucolytic effect: Use as granules dissolved in water.

  • Adults: 200 mg (1 capsule) three times daily.
  • Children aged 2 to 6 years old: 200 mg (1 capsule) twice daily.
    (Hard gelatin capsule is not a suitable dosage form for children under 03 years old, the other suitable dosage forms are recommended).

Antidote for paracetamol overdosage:

An initial dose of 140 mg/kg as a 5% solution followed by 70 mg/kg every 4 hours for additional 17 doses. Acetylcysteine is reported to be very effective when administered within 8 hours of paracetamol overdosage, with the protective effect diminishing after this time.


Stacytine 200 CAP is administered orally.

  • Known hypersensitivity to acetylcysteine or any ingredient in the preparation.
  • Patients with asthma or a history of bronchospasm.
  • Children under 2 years old.
  • Hypersensitivity:
    Bronchospasm, angioedema, rashes and pruritus; hypotension, or occasionally hypertension, may occur.
  • Other adverse effects:
    Flushing, nausea and vomiting, fever, syncope, sweating, arthralgia, blurred vision, disturbances of liver function, acidosis, convulsions, and cardiac or respiratory arrest.
  • Since oral administration of acetylcysteine may result in vomiting or aggravate vomiting associated with paracetamol overdosage, patients at risk of gastric hemorrhage should be evaluated with regard to the relative risks of upper gastrointestinal hemorrhage and paracetamol-induced hepatotoxicity and treatment with acetylcysteine given accordingly.
  • Asthmatic patients receiving acetylcysteine should be observed closely during such therapy; if bronchospasm occurs, a bronchodilator should be given by nebulization. If bronchospasm progresses, acetylcysteine should be discontinued immediately.
  • An increased volume of liquefied bronchial secretions may develop after administration of acetylcysteine. If cough is inadequate to maintain an open airway during acetylcysteine therapy, mechanical suction or endotracheal aspiration should be instituted.
  • Stacytine 200 CAP contains lactose and wheat starch. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption, wheat allergy (different from coeliac disease) should not take this medicine.
  • Stacytine 200 CAP can be used for pregnant and nursing women.
  • Patients should be aware of how they react to Stacytine 200 CAP before driving or operating machinery.